Cost-effectiveness of letrozole in the treatment of advanced breast cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 4, 2004, Pages 383-391

  Karnon, Jonathan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Breast cancer; Cost effectiveness; Letrozole; Second line therapy

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EXEMESTANE; FLUOROURACIL; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; ECONOMIC EVALUATION; HEALTH CARE SYSTEM; HORMONE SENSITIVITY; HUMAN; METASTASIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIDE EFFECT;

EID: 4444228354     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.4.383     Document Type: Article

References (27)

1. Will BP, Berthelot J-M, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur. J. Cancer 36, 724-735 (2000).
2. Stockler M, Wilcken NRC, Ghersi D, John Simes R. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat. Rev. 26, 151-168 (2000).
3. Haller DG, Fox KR, Schucter LM. Metastatic breast cancer. In: Breast Cancer Treatment: a Comprehensive Guide to Management. Fowble B, Goodman RL, Glick JH, Rosato EF (Eds). Mosby Year Book, MO, USA (1991).
4. Simon MS, Ibrahim D, Newman L, Stano M. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 19, 453-463 (2002).
5. Simpson D, Curran MP, Perry CM. Letrozole. A review of its use in postmenopausal women with breast cancer. Drugs 64(11), 1213-1230 (2004).
6. Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev. Anticancer Ther. 3, 193-201 (2003).
7. Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethamide in postmenopausal women with advanced breast cancer. Ann. Oncology 9, 645 (1998).
8. Jonat W, Howell A, Bloqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex®) with MA in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404-412 (1996).
9. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new aromatase inhibitor for advanced breast cancer. Double-blind randomised trial showing a dose effect and improved efficacy and tolerability comapred with megestrol acetate. J. Clin. Oncol. 16, 453-461 (1998).
10. Buzdar AU, Jones SE, Vogel CL et al. A Phase III trial comparing anastrozole (1 and 10 mg), a potent and slective aromatase inhibitor, with MA in postmenopausal women with advanced breast carcinoma. Cancer 79, 730-739 (1997).
11. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin. Cancer Res. 4, 527-34 (1998).
12. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J. Surgical Oncol. 77, 139-147 (2001).
13. Mouridsen H, Gershanovich M, Sun Y. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19, 2596-2606 (2001).
14. Nabholtz JM, Buzdar AU, Pollak W et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. J. Clin. Oncol. 18, 3758-3767 (2000).
15. Nuijten M, Meester L, Waibel F, Wait S. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. PharmacoEconomics 16, 379-397 (1999).
16. Nuijten M, Fitzimon C, Waild F. Economic evaluation of letrozole in the treatment of advanced breast cancer inpostmenopausal women in Canada. Value Health 3(1), 31-39 (2000).
17. Dranitsaris G, Leung PP, Mather J et al. Cost-utility analysis of second line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 11, 591-601 (2000).
18. Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91, 484-489 (2001).
19. Verma S, Rocchi A. Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer 11, 728-734 (2003).
20. Karnon J, Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients. PharmacoEconomics 21, 513-525 (2003).
21. Karnon J, Johnston SRD, Jones T, Glendenning A. A trial-based economic evaluation of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal, advanced breast cancer. Ann. Oncol. (2003).
22. Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer. Comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. 26, 289-296 (2003).
23. Delea T, Smith R, Karnon J. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy for postmenopausal women with advanced breast cancer: the US perspective. J. Clin. Oncol. 542 (2002).
24. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J. Clin. Oncol. 17, 3082-3090 (1999).
25. Hillner BE, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91, 484-489 (2001).
26. Goss PE, Ingle JN, Martino S et al. A randomised trial of letrozole in postmenoapusal women after 5 years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349(19), 1793-1802 (2003).
27. Karnon J, Johnston SRD, Delea T et al. Cost-effectiveness of extended adjuvant letrozole after 5 years of tamoxifen in postmenopausal early breast cancer. ASCO (2004) (In Press).